Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with Induction and Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma
NCT03932266Phase 2Unknown
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jun 2019
- Primary completion
- Sep 2022
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 2, randomised, open-label trial of endostar in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
endostar
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03932266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932266.